- Home
- ELDN vs IXHL Comparison
ELDN vs IXHL Comparison
Compare ELDN & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELDN | IXHL |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.6M | 97.6M |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ELDN | IXHL |
|---|---|---|
| Price | $2.69 | $3.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 900.4K | ★ 4.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $0.11 |
| 52 Week High | $4.60 | $6.39 |
Technical Indicators
Market Signals| Indicator | ELDN | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | 56.66 |
| Support Level | $2.48 | $0.31 |
| Resistance Level | $2.77 | $5.17 |
| Average True Range (ATR) | 0.21 | 0.45 |
| MACD | 0.02 | 0.23 |
| Stochastic Oscillator | 54.23 | 49.80 |
Price Performance
Historical ComparisonAbout ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.